Zobrazeno 1 - 10
of 487
pro vyhledávání: '"Udo Jonas"'
Autor:
Klaus, Höfner, Udo, Jonas
Publikováno v:
World journal of urology. 19(6)
A once-daily (o.d.) formulation of alfuzosin has recently been developed in order to improve the convenience of dosing and to provide optimal pharmacokinetic coverage over a 24-h period. The results of two double-blind, placebo-controlled phase III s
Autor:
Karl P Odenthal, Christian Georg Stief, Udo Jonas, Stefan Ückert, Burckhard Lietz, Michael C. Truss
Publikováno v:
Arzneimittelforschung. 50:456-460
The spasmolytic activity of flavoxate (CAS 15301-69-6) and the anticholinergic agents oxybutynin (CAS 5633-20-5), tolterodine (CAS 124937-51-5) and trospium chloride (CAS 10405-02-4), all of which are commonly utilized in the treatment of urinary inc
Publikováno v:
World Journal of Urology. 28:353-357
To investigate the symptomatic and quality of life (QoL) response to treatment with tolterodine extended release (ER) in subgroups of male patients with Overactive Bladder Syndrome (OAB) and LUTS suggestive of non-obstructive benign prostatic hyperpl
Publikováno v:
World Journal of Urology. 26:603-609
To date, there is an increasing interest in the nitric oxide (NO) pathway as a potential pharmacological target to treat male lower urinary tract symptomatology (LUTS). In the transition zone of the human prostate, a dense nitrinergic innervation has
Autor:
C. G. Stief, Michael C. Truss, Matthias Oelke, Mohamad H. Djamilian, Udo Jonas, Ernst P. Allhoff, M.A. Kuczyk
Publikováno v:
Aktuelle Urologie. 26:334-338
Autor:
Wolfram H. Knapp, Christian G. Stief, George T. Kedia, Udo Jonas, Stefan Ückert, Friedemann Scheller, Michael Sormes
Publikováno v:
Urology. 71:526-530
Objectives To further evaluate the mechanism of action of phosphodiesterase (PDE) inhibitors on the human prostate, the effects of PDE4 and PDE5 inhibitors on the tension induced by norepinephrine (NE) and on the intracellular levels of cyclic nucleo
Autor:
Petter Hedlund, Udo Jonas, Michael Seidler, Stefan Ückert, J.E. Sonnenberg, Eginhard S. Waldkirch
Publikováno v:
The Journal of Sexual Medicine. 5:69-73
Autor:
Klaus Höfner, Matthias Oelke, Joyce Baard, Hessel Wijkstra, Jean J.M.C.H. de la Rosette, Udo Jonas
Publikováno v:
European urology, 54(2), 419-426. Elsevier
European Urology, 54(2), 419-426. Elsevier
European Urology, 54(2), 419-426. Elsevier
Background: Detrusor overactivity is one known cause of lower urinary tract Symptoms and has been linked to bladder storage symptoms (urgency, frequency, or urge incontinence). Objective: To determine clinical and urodynamic parameters associated wit
Publikováno v:
World Journal of Urology. 25:627-633
Patients with presumed non-obstructive BPH (Q (max )or= 15 ml/s) treated with tolterodine ER 4 mg/day for OAB symptoms, alone or added to unsuccessful alpha-blocker treatment ofor=6 weeks duration, were observed for 12 weeks in a non-interventional s
Autor:
E.S. Waldkirch, Udo Jonas, Gerald Wolf, Christian G. Stief, Karl-Erik Andersson, Petter Hedlund, Karin Richter, S. Ückert, Kristina Langnäse
Publikováno v:
European Urology. 52:495-502
Objectives Phosphodiesterase 5 (PDE5) inhibitors improve smooth muscle relaxation and therefore are considered for pharmacotherapy of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Cyclic guanosine monophosphate (cGMP)-de